David A. Siegel Ikena Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 202,100 shares of IKNA stock, worth $313,255. This represents 0.0% of its overall portfolio holdings.
Number of Shares
202,100
Previous 173,200
16.69%
Holding current value
$313,255
Previous $285,000
22.46%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding IKNA
# of Institutions
61Shares Held
30.6MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$7.78 Million1.07% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$7.39 Million0.26% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$6.34 Million2.33% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$5.49 Million0.14% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.49 Million5.77% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $56.2M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...